Preclinical and Clinical Research on the Efficacy of Anticancer Drugs
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 31 March 2025 | Viewed by 53
Special Issue Editors
Interests: leukemia; cell transplantation; cancer therapy; hematologic malignancies
Interests: metabolic disorders; epigenetics; cancer genetics; gene expression
Special Issue Information
Dear Colleagues,
“Preclinical and Clinical Research on the Efficacy of Anticancer Drugs" explores the comprehensive evaluation processes involved in the development of cancer therapies. This field encompasses both preclinical studies, which involve laboratory and animal testing to determine the safety and biological activity of new drugs, and clinical trials, which assess their therapeutic effectiveness and safety in human patients. The integration of these studies is crucial for identifying promising anticancer agents, optimizing their formulations, and ensuring they meet regulatory standards before reaching the market.
Authors are encouraged to present findings that contribute to understanding drug mechanisms, improving trial methodologies, and developing novel therapeutic strategies. Original research articles and review articles are welcome.
Prof. Dr. Andrzej Hellmann
Prof. Dr. Joanna Jakobkiewicz-Banecka
Dr. Jan Lica
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- clinical trials
- preclinical research
- anticancer drugs
- drug efficacy
- drug development
- cancer therapy
- therapeutic strategies
- safety assessment
- pharmacodynamics
- pharmacokinetics
